Detalhe da pesquisa
1.
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Blood
; 143(16): 1616-1627, 2024 Apr 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38215395
2.
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Blood
; 139(22): 3278-3289, 2022 06 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35196370
3.
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Blood
; 140(2): 112-120, 2022 07 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35427411
4.
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Blood
; 138(26): 2810-2827, 2021 12 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34407545
5.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
Inglês
| MEDLINE | ID: mdl-33259589
6.
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
Haematologica
; 2023 Oct 19.
Artigo
Inglês
| MEDLINE | ID: mdl-37855051
7.
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
Future Oncol
; 2023 01 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36617990
8.
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
N Engl J Med
; 381(5): 432-443, 2019 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31365801
9.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood
; 136(10): 1134-1143, 2020 09 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32688395
10.
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
N Engl J Med
; 379(26): 2517-2528, 2018 12 27.
Artigo
Inglês
| MEDLINE | ID: mdl-30501481
11.
How I treat early-relapsing follicular lymphoma.
Blood
; 133(14): 1540-1547, 2019 04 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30700421
12.
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.
Blood
; 134(15): 1238-1246, 2019 10 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31331918
13.
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Blood
; 133(19): 2031-2042, 2019 05 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30842083
14.
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
Br J Haematol
; 188(6): 918-923, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31682002
15.
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
Blood
; 132(3): 293-306, 2018 07 19.
Artigo
Inglês
| MEDLINE | ID: mdl-29695516
16.
Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.
Br J Haematol
; 186(2): 255-262, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31044423
17.
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs.
Oncologist
; 24(11): e1236-e1250, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31346132
18.
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Blood
; 129(19): 2612-2615, 2017 05 11.
Artigo
Inglês
| MEDLINE | ID: mdl-28373262
19.
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Invest New Drugs
; 37(2): 297-306, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30132271
20.
ALK-rearranged CD30-positive poorly differentiated lung adenocarcinoma, mimicking anaplastic large-cell lymphoma.
Histopathology
; 84(5): 900-902, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38032068